An Exploratory Study by Fast CAR T Cells - Trial NCT06327997
Access comprehensive clinical trial information for NCT06327997 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Cell Therapy Group Co.,Ltd and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Cell Therapy Group Co.,Ltd
Timeline & Enrollment
Phase 1
Mar 07, 2024
Dec 31, 2027
Primary Outcome
Dose-limiting toxicity(DLT)
Summary
The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy
 for advanced solid tumors with positive mesothelin and MUC1.Patients were screened,
 peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells
 were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were
 infused on day 0 (the dose was determined according to the requirements of
 climbing/expansion). The safety intensive observation period was 28 days after infusion, and
 the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation
 and evaluation were carried out according to the follow-up visit point, and the follow-up
 period was 1 year. From the second year, the telephone follow-up period was entered.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06327997
Non-Device Trial